Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient’s own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to “turn back the clock” and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
“We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases,” said Susan L. Solomon, NYSCF Chief Executive Officer.
The Latest on: Cell replacement therapy
via Google News
The Latest on: Cell replacement therapy
- Gene therapeutic strategies and relevant clinical trials in neuromuscular disorder in Chinaon June 26, 2020 at 8:20 am
Cell. 1995;80:155–65. Groen EJN ... Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med.
- CSL Behring pays $450M to strengthen gene therapy pipelineon June 25, 2020 at 8:57 am
King of Prussia's CSL Behring acquires gene therapy candidate in a deal that includes a $450M upfront payment.
- CSL acquires haemophilia gene therapy rights for $656mon June 24, 2020 at 7:06 pm
CSL is expanding its work in gene therapy by buying the rights to UniQure's therapy for haemophilia B, which is already in phase three clinical trials.
- CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQureon June 24, 2020 at 3:48 pm
Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 ...
- Worldwide Stem Cell Therapy Industry to 2027 - Growth in the Global Healthcare Market Presents Opportunitieson June 18, 2020 at 8:38 am
Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
- Global Stem Cell Therapy Market (2019 to 2027) - by Type, Treatment, Application, End-user, and Geographyon June 18, 2020 at 1:38 am
The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report ha ...
- Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe diseaseon June 16, 2020 at 5:11 pm
Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease * Avalglucosidase alfa showed a 2.4-point improvement ...
- Sanofi enzyme replacement therapy shows mixed results in Pompe studyon June 16, 2020 at 10:24 am
Sanofi (NASDAQ:SNY) announces positive results from a Phase 3 clinical trial, COMET, evaluating avalglucosidase alfa, an enzyme replacement therapy, in patients with late-onset Pompe disease, an inher ...
- Millimeter-thick cell-laden hydrogel fiber helps control blood glucose in diabetic miceon June 15, 2020 at 7:33 pm
Type 1 diabetes mellitus results from an irreversible autoimmune destruction of insulin-producing pancreatic β-cells requiring life-long substitution of insulin.
- Diabetic mice improve with retrievable millimeter-thick cell-laden hydrogel fiberon June 15, 2020 at 8:08 am
Type 1 diabetes mellitus (T1DM) results from an irreversible autoimmune destruction of insulin-producing pancreatic β-cells requiring life-long substitution of insulin. In a new study, researchers at ...
via Bing News